Reported about 4 hours ago
This winter, the US is experiencing a significantly smaller wave of COVID-19 cases, creating additional pressure on Pfizer to boost growth through its non-COVID treatments. Pfizer's stock prices have dropped as sales from COVID products decline sharply, while investors demand better performance from its cancer drugs. Despite expectations of a slight increase in earnings, the company may not see a resurgence in COVID cases as immunity builds among the population.
Source: YAHOO